{"id":390954,"date":"2017-06-21T00:00:00","date_gmt":"2017-06-21T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/emthon0005-2017-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-emerging-therapies-venclexta-venetoclax\/"},"modified":"2026-03-31T09:01:04","modified_gmt":"2026-03-31T09:01:04","slug":"emthon0005-2017-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-emerging-therapies-venclexta-venetoclax","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/emthon0005-2017-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-emerging-therapies-venclexta-venetoclax\/","title":{"rendered":"Non-Hodgkin&#8217;s Lymphoma and Chronic Lymphocytic Leukemia | Emerging Therapies | Venclexta (venetoclax) | US | Wave 3 | 2017"},"content":{"rendered":"<p>Venclexta (Wave 3) is the third in a multiwave series designed to track physician perception and uptake of as well as the competitive environment for the newly launched chronic lymphocytic leukemia (CLL) drug Venclexta (Roche\/Genentech\u2019s venetoclax). Launch Tracking Venclexta measures the impact of this novel agent on the relapsed\/refractory CLL with del(17p) therapy market following launch, based on a blend of quantitative and qualitative primary research with U.S. hematologist-oncologists. This content evaluates physicians\u2019 current awareness and perception of Venclexta relative to other currently available therapies for relapsed\/refractory CLL, current and anticipated use of Venclexta, and promotional activity for Venclexta.<\/p>\n<p><strong>What you will learn in this content:<\/strong><\/p>\n<ul>\n<li>What is U.S. hematologist-oncologists\u2019 awareness of and familiarity with Venclexta, and what are their perceptions of this product?<\/li>\n<li>Among prescribers, for which patients are they prescribing Venclexta, what are the reasons for prescribing, and how satisfied are they with Venclexta?<\/li>\n<li>What promotional messages and activities are Roche\/Genentech employing in support of the Venclexta launch?<\/li>\n<li>How do prescribers and nonprescribers compare across key metrics?<\/li>\n<li>How is the trial and adoption of Venclexta tracking compared with other recent first-in-class product launches in the oncology market?<\/li>\n<\/ul>\n<p><strong>Methodology: <\/strong>~75-100 U.S. hematologist-oncologists complete a 30-minute online quantitative survey with several open-ended questions for qualitative feedback. In addition, ten surveyed specialists participate in a 30-minute follow-up qualitative interview.<\/p>\n<p><strong>Related reports: <\/strong>Venclexta Launch Tracking (US) Wave 1, Venclexta Launch Tracking (US) Wave 2, Derzalex\/Emplicity Launch Tracking (US) Wave 3<\/p>\n","protected":false},"template":"","class_list":["post-390954","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hodgkins-lymphoma","biopharma-therapy-areas-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia","biopharma-product-emerging-therapies","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390954","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390954\/revisions"}],"predecessor-version":[{"id":394078,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390954\/revisions\/394078"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}